Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion

Blood

Volumn 96, Issue 3, 2000, Pages 864-869

  Magni, M ^a   Di Nicola, M ^a   Devizzi, L ^a   Matteucci, P ^a   Lombardi, F ^a   Gandola, L ^a   Ravagnani, F ^a   Giardini, R ^a   Dastoli, G ^a   Tarella, C ^a   Pileri, A ^a   Bonadonna, G ^a   Gianni, A M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOTHERAPY; IN VIVO STUDY; MALE; MANTLE CELL LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0034254354     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.3.864.015k26_864_869     Document Type: Article

References (34)

1. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury
2. High-dose therapy and transplantation for low-grade lymphoma
3. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML
4. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
5. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells
6. High dose therapy and autologous stem cell transplantation in follicular non-Hodgkin's lymphoma
7. Purging marrow or peripheral blood stem cells for autografting
8. Should we purge?
9. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's Lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting
10. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
11. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
12. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
13. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
14. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma
15. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patents with renal insufficiency
16. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results
17. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
18. High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease - A 6- year update
19. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patient with high-risk multiple myeloma
20. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients
21. + cells [abstract]
22. Improved collection of mobilized CD34+ hematopoietic progenitor cells by a novel automated leukapheresis system
23. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease
24. Benefits of blood cell transplant cryopreservation with oxypolygelatin (Gelifundol) plasma substitute
25. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
26. Diffuse small-cell lymphomas
27. Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: Short intervals between drug courses severely impair progenitor mobilization
28. Collection of normal blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia
29. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission
30. In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation
31. In vivo purging of residual disease in CLL with Campath-1H
32. Mobilization of peripheral stem cells with intensive chemotherapy (ICE regimen) and G-CSF in chronic myeloid leukemia
33. Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: Evidence for long term clinical and molecular remission
34. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer